Coherus OncologyFRA:8C5 -2.10%49 PS Ratio is 4.24 as of Jul. 12, 2026, which is 15% above its 10-year median of 3.69. GuruFocus rates FRA:8C5 with a GF Score™ of 49/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, Coherus Oncology ranks better than 72.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Coherus Oncology's share price is €1.399.
Coherus Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.33. Hence, Coherus Oncology's PS Ratio for today is 4.24.
The historical rank and industry rank for Coherus Oncology's PS Ratio or its related term are showing as below:
FRA:8C5'
s PS Ratio Range Over the Past 10 Years
Min: 0.6 Med: 3.69 Max: 746.3
Current: 4.04
During the past 13 years, Coherus Oncology's highest PS Ratio was 746.30. The lowest was 0.60. And the median was 3.69.
FRA:8C5's PS Ratio is ranked better than 72.47% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs FRA:8C5: 4.04
Coherus Oncology Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Coherus Oncology was 39.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -49.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -47.60% per year.
During the past 13 years, Coherus Oncology's highest 3-Year average Revenue per Share Growth Rate was 481.40% per year. The lowest was -80.30% per year. And the median was -17.60% per year.
Back to Basics: PS Ratio
Coherus Oncology (FRA:8C5) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Coherus Oncology PS Ratio Related Terms
Coherus Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coherus Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Coherus Oncology's Share Price of today is €1.399. Coherus Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Coherus Oncology (FRA:8C5) has a PS Ratio of 4.24 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Coherus Oncology and its competitors. This is 15% above median its historical median of 3.69. Over the past decade, Coherus Oncology's PS Ratio has ranged from 0.60 to 746.30. According to the industry distribution chart, Coherus Oncology ranks #256 out of 930 companies in the Biotechnology industry, placing it in the top 27.5%.
Is Coherus Oncology's PS Ratio too high?
Coherus Oncology's current PS Ratio of 4.24 is 15% above median its 10-year median of 3.69. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 746.30. The Biotechnology industry median PS Ratio is 9.51. Coherus Oncology's value of 4.24 is 55.4% below this industry median. Based on the distribution chart, Coherus Oncology ranks #256 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's PS Ratio compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #256 out of 930 companies for PS Ratio. This puts Coherus Oncology in the upper half of its industry. The industry median PS Ratio is 9.51. Coherus Oncology's value of 4.24 is 55.4% below this benchmark. Historically, Coherus Oncology's own PS Ratio has ranged from 0.60 to 746.30 over the past decade. While the company's 10-year median is 3.69 vs. the industry median of 9.51, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.51, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current PS Ratio of 4.24 is 55.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current PS Ratio is 4.24, which is 15% above median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €1.40 — trading 118.6% above its estimated fair value. The current PS Ratio is 4.24, which is 15% above median its 10-year median of 3.69 and 55.4% below the Biotechnology industry median of 9.51. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current PS Ratio is 4.24 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.40 is trading 118.6% above its estimated GF Value™ of €0.64.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
PS Ratio: 4.24 (15% above median its 10-year median of 3.69)
GF Value™: €0.64 vs. price of €1.40 (118.6% above fair value)
Industry Position: 55.4% below the Biotechnology median (#256 of 930)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
